We came across a bullish thesis on CorMedix Inc. (CRMD) on Archetype Capital’s Substack. In this article, we will summarize the bulls’ thesis on CRMD. CorMedix Inc. (CRMD)’s share was trading at $14.86 as of 12th June. CRMD’s trailing and forward P/E were 59.44 and 22.88 respectively according to Yahoo Finance.
A close up photograph of a vial of a new biotechnological drug candidate in development.
CorMedix offers a compelling, asymmetric investment opportunity built not on speculative biotech development but on a proven, FDA-approved product addressing a large, costly clinical problem. Its flagship therapy, DefenCath, is designed to prevent catheter-related bloodstream infections (CRBSIs) in dialysis patients—a condition that afflicts up to 25% of patients with central venous catheters and costs the healthcare system an average of $63,000 per case. DefenCath is a taurolidine-based catheter lock solution paired with heparin, optimized for U.S. dialysis protocols, and inspired by the success of Europe’s TauroLock.
Following a clinical trial showing a 71% reduction in infections, DefenCath received FDA approval in November 2023 and will begin outpatient rollout under Medicare’s TDAPA program in July 2024.
CorMedix has already secured contracts with four of the five largest dialysis organizations, collectively covering about 70% of its estimated 170,000-patient TAM. While only one has begun implementation, broader rollout is expected imminently.
Even in an ultra-conservative worst-case scenario—assuming just 10,000 patients, a steep price erosion to $50 per vial, and zero Medicare carve-out support—the stock still supports a terminal value double its current market cap. This pricing scenario assumes clinics absorb all costs once TDAPA ends, despite a strong precedent for Medicare or Medicare Advantage carving out innovative therapies that lower systemic costs. With every prevented infection potentially saving tens of thousands in hospitalizations, DefenCath at $250 per vial could remain economically attractive, especially as Medicare Advantage—which covers both dialysis and hospitalizations—grows in share.
CorMedix is proactively preparing for post-TDAPA reimbursement negotiations, anchored by a real-world evidence (RWE) study tracking over 2,000 patients at US Renal Care. Results, expected in July, will assess reductions in infections, antibiotic use, hospitalizations, and mortality—data that could directly support pricing sustainability and Medicare carve-outs.
Importantly, DefenCath benefits from regulatory exclusivity through 2033 and faces no FDA-approved taurolidine-based competitors in the U.S., giving it a unique market position. Like sugammadex before it, which overcame regulatory delays to become a U.S. standard-of-care after European success, DefenCath is positioned to transform a proven European antimicrobial strategy into a U.S. standard with substantial commercial potential.
Previously, we covered a bullish thesis on CorMedix (CRMD) by gamblingPharmaStocks, focusing on DefenCath’s strong clinical data, favorable reimbursement via TDAPA, and promising early sales in the outpatient dialysis market. Since our coverage the stock price has appreciated by rougly 33% Archetype Capital echoes this optimism but emphasizes CorMedix’s deeply asymmetric risk/reward, major dialysis contracts covering 70% of its TAM, and upcoming real-world evidence that could solidify post-TDAPA pricing—arguing that even conservative uptake scenarios justify a valuation well above current levels.
CorMedix Inc. (CRMD) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 12 hedge fund portfolios held CorMedix Inc. (CRMD) at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the risk and potential of CRMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.
Disclosure: None. This article was originally published at Insider Monkey.
